394.03
前日終値:
$393.48
開ける:
$394.15
24時間の取引高:
679.87K
Relative Volume:
1.41
時価総額:
$27.73B
収益:
$3.22B
当期純損益:
$542.70M
株価収益率:
52.67
EPS:
7.4805
ネットキャッシュフロー:
$458.00M
1週間 パフォーマンス:
+2.87%
1か月 パフォーマンス:
+6.18%
6か月 パフォーマンス:
+43.59%
1年 パフォーマンス:
+42.25%
West Pharmaceutical Services Inc Stock (WST) Company Profile
名前
West Pharmaceutical Services Inc
セクター
電話
(610) 594-2900
住所
530 HERMAN O. WEST DRIVE, EXTON, PA
Compare WST vs ISRG, BDX, RMD, ALC, MDLN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services Inc
|
394.03 | 27.73B | 3.22B | 542.70M | 458.00M | 7.4805 |
|
ISRG
Intuitive Surgical Inc
|
443.85 | 156.80B | 11.03B | 3.16B | 3.22B | 8.7251 |
|
BDX
Becton Dickinson Co
|
200.42 | 54.59B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
RMD
Resmed Inc
|
253.06 | 35.59B | 5.54B | 1.52B | 1.74B | 10.37 |
|
ALC
Alcon Inc
|
70.63 | 34.14B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
MDLN
Medline Inc
|
34.88 | 30.60B | 29.14B | 1.07B | 1.05B | 1.1956 |
West Pharmaceutical Services Inc Stock (WST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-09-22 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2026-09-09 | 再開されました | UBS | Buy |
| 2026-07-13 | 開始されました | BNP Paribas Exane | Outperform |
| 2026-06-09 | アップグレード | Barclays | Equal Weight → Overweight |
| 2026-06-02 | 再開されました | Wolfe Research | Outperform |
| 2025-12-02 | 開始されました | Morgan Stanley | Equal-Weight |
| 2025-09-15 | 開始されました | Rothschild & Co Redburn | Buy |
| 2025-06-24 | 開始されました | Barclays | Equal Weight |
| 2025-03-18 | 開始されました | Evercore ISI | Outperform |
| 2025-02-14 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-01-08 | 開始されました | Citigroup | Buy |
| 2024-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2024-12-12 | アップグレード | UBS | Neutral → Buy |
| 2024-02-07 | アップグレード | Jefferies | Hold → Buy |
| 2023-06-16 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-04-11 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2022-12-14 | 開始されました | Deutsche Bank | Hold |
| 2022-11-30 | 開始されました | UBS | Neutral |
| 2022-10-28 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2020-10-14 | 開始されました | Stephens | Equal-Weight |
| 2020-07-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2020-04-24 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-12-12 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2019-07-26 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-05-01 | ダウングレード | Jefferies | Buy → Hold |
| 2019-04-23 | 開始されました | William Blair | Outperform |
| 2018-04-25 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2018-01-24 | 開始されました | Goldman | Neutral |
| 2017-10-17 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2017-10-03 | 開始されました | Stephens | Equal-Weight |
| 2017-09-15 | アップグレード | Jefferies | Hold → Buy |
| 2016-10-28 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2016-09-21 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2016-03-22 | 開始されました | Wells Fargo | Outperform |
| 2010-05-14 | 繰り返されました | UBS | Neutral |
| 2010-02-23 | 開始されました | Jefferies & Co | Buy |
| 2008-12-19 | 開始されました | UBS | Neutral |
すべてを表示
West Pharmaceutical Services Inc (WST) 最新ニュース
West Pharmaceutical Services Inc Unsponsored Brazilian Depositary Receipt Repr 0.0285714 Sh - TradingView
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day - MarketWatch
West Pharmaceutical Services, I (WST) Stock Forecasts - Yahoo! Finance Canada
West Pharmaceutical Services, I (WST) Stock Forecasts - Yahoo Finance
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day - MarketWatch
West Pharmaceutical Services (WST) Raises Quarterly Dividend by 18.2% - GuruFocus
West Pharmaceutical Services Raises Quarterly Dividend 18% to $0.26 a Share, Payable Nov. 18 to Holders as of Nov. 11. - marketscreener.com
West Declares Quarterly Dividend - PR Newswire
A company has raised its dividend for 34 straight years. Its next payment is $0.26 per share. - Stock Titan
Press Release: West Declares Quarterly Dividend - Moomoo
3 Low-Volatility Stocks We’re Skeptical Of - FinancialContent
West Pharmaceutical Sets October 29 Earnings Release - MyChesCo
West Pharmaceutical Services (NYSE:WST): What Does the S&P 500 Context Reveal? - Kalkine Media
West Pharmaceutical Services stock hits 52-week high at $386.08 By Investing.com - Investing.com South Africa
West Pharmaceutical Services stock hits 52-week high at $386.08 - Investing.com
West Pharmaceutical Services stock hits 52-week high at $386.08 By Investing.com - Investing.com Nigeria
West Pharmaceutical Services Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
West Pharmaceutical Services Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
What Do West Pharmaceutical Services' Latest Results Reveal About This S&P 500 Stock (NYSE:WST)? - Kalkine Media
West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally? - TradingView
West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally? - Yahoo Finance
Meta, JPMorgan, West Pharmaceutical And More: CNBC’s ‘Final Trades’ - Benzinga
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day - MarketWatch
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Zacks Investment Research
Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms - Zacks Investment Research
TD Cowen Adjusts Price Target on West Pharmaceutical Services to $420 From $410 - Yahoo Finance
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y - Zacks Investment Research
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now - Zacks Investment Research
Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets - Zacks Investment Research
Here's Why You Should Retain WAT Stock in Your Portfolio for Now - Zacks Investment Research
Third-quarter results are due before markets open Oct. 29; West Pharmaceutical's call follows at 8 a.m. - Stock Titan
West Pharmaceutical Services Needs Faster Earnings Growth To Justify Its Price (NYSE:WST) - Seeking Alpha
West Pharmaceutical Services (WST) Stock Could Be 17% Overvalued As Cash Flow Falls Short - Yahoo Finance
West Pharmaceutical Services Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now - Zacks Investment Research
BDX Expands U.S. Manufacturing With $19B Healthcare Investment - Zacks Investment Research
Reasons to Hold HealthEquity Stock in Your Portfolio for Now - Zacks Investment Research
Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies - Zacks Investment Research
West Pharmaceutical: Still A Buy, But Expectations Are Rising - Seeking Alpha
PCR Packaging For Pharma And Otc Market 7.2% CAGR to 2035 on ESG MandatesNews and Statistics - IndexBox
GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal - TradingView
Reasons to Retain Cardinal Health Stock in Your Portfolio for Now - Zacks Investment Research
Reasons to Retain Cardinal Health Stock in Your Portfolio for Now - TradingView
Barclays Raises West Pharmaceutical Services Price Target to $440 From $400, Maintains Overweight Rating - marketscreener.com
West Pharmaceutical Services Highlights Leadership & Expertise - Contract Pharma
Is West Pharmaceutical Services Inc (WST) Overvalued After 3.2% - GuruFocus
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day - MarketWatch
Reasons to Retain Doximity Stock in Your Portfolio for Now - Zacks Investment Research
What to Expect From West Pharmaceutical Services' Next Quarterly Earnings Report - Yahoo Finance
What to Expect From West Pharmaceutical Services' Next Quarterly Earnings Report - inkl
West Pharmaceutical Services Inc (WST) 財務データ
収益
当期純利益
現金流量
EPS
West Pharmaceutical Services Inc (WST) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 15 '26 |
Sale |
365.00 |
2,524 |
921,260 |
21,818 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 14 '26 |
Sale |
355.00 |
2,500 |
887,500 |
21,818 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 11 '26 |
Sale |
345.00 |
2,500 |
862,500 |
21,818 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 11 '26 |
Option Exercise |
89.64 |
2,500 |
224,100 |
24,318 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 11 '26 |
Option Exercise |
89.64 |
2,500 |
224,100 |
24,318 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 08 '26 |
Option Exercise |
85.37 |
8,135 |
694,453 |
19,663 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 08 '26 |
Sale |
340.81 |
8,135 |
2,772,489 |
16,845 |
| Hofmann Thomas W | Director |
May 07 '26 |
Proposed Sale |
322.12 |
3,384 |
1,090,051 |
0 |
| Winters Chad | VP, Chief Accounting Officer |
Apr 27 '26 |
Sale |
300.67 |
896 |
269,399 |
1,523 |
| Winters Chad | VP, Chief Accounting Officer |
Apr 27 '26 |
Option Exercise |
173.22 |
896 |
155,205 |
2,419 |
大文字化:
|
ボリューム (24 時間):